

# T2Direct Diagnostics™

SAME DAY targeted therapy starts in the lab

## Early targeted therapy starts in the lab

T2Direct Diagnostics, the only FDA-cleared, CE-marked suite of products, identifies deadly sepsis-causing pathogens directly from whole blood without the wait for blood culture results, delivers faster, easier and more accurate results in 3 to 5 hours.

Now, physicians can deliver same day targeted therapy

**in hours versus days.**

- Quickly administer targeted therapy or de-escalation of therapy
- May prevent progression to sepsis
- Potentially reduce morbidity and mortality outcomes
- Reduce resistance while improving antimicrobial stewardship
- Reduce the costs of sepsis management

\*A combination of samples was run in both the prospective and contrived arms of the study. T2Bacteria showed an overall average sensitivity of 90% in the prospective arm of the study, with an overall average PPA of 97% in the contrived arm of the study.

## T2Dx® Instrument

- Direct from whole blood
- Results in 3 to 5 hours
- As low as 1 CFU/mL LoD
- Easy to operate
- Cartridge-based



T2Dx panels identify the most **deadly and prevalent species** that are not often covered by broad-spectrum therapy.

## T2Bacteria® Panel\*

95.8% Sensitivity\* | 98.2% Specificity<sup>1</sup>

- *Enterococcus faecium*
- *Staphylococcus aureus*
- *Klebsiella pneumoniae*
- *Acinetobacter baumannii*
- *Pseudomonas aeruginosa*
- *Escherichia coli*

## T2Candida® Panel

91.1% Sensitivity | 99.4% Specificity<sup>2</sup>

- *Candida albicans*
- *Candida tropicalis*
- *Candida krusei*
- *Candida glabrata*
- *Candida parapsilosis*



**T2 Biosystems®**

t2biosystems.com • +1 781-457-1200

# T2Direct Diagnostics


Early identification faster than ever



## Breakthrough technology enabling direct detection from whole blood

The T2Dx Instrument is an easy to use, fully-automated, random access benchtop diagnostic system that enhances sepsis management with rapid, actionable species identification. Busy lab technicians can count on T2Direct Diagnostics to deliver a consistent, high quality result.

## Redefining rapid diagnostics



## Deliver exceptional patient care

Sepsis is managed through rapid interventions, including prompt administration of broad-spectrum empiric therapy. While waiting days for blood culture results, initial empiric therapy is often changed multiple times in an effort to get patients on the right therapy as fast as possible. By screening suspected patients at the first sign of infection, physicians can start targeted therapy far faster, potentially preventing the onset of sepsis and increasing the odds of both survival and a rapid recovery.

## T2Dx Instrument

- Fully-automated benchtop design
- Random access workflow
- “Sample in — results out” processing
- Minimal specimen handling
- LoD as low as 1 CFU/mL
- Cartridge-based

To learn more about the T2Direct Diagnostics, email

[info@t2biosystems.com](mailto:info@t2biosystems.com) or visit [www.t2biosystems.com](http://www.t2biosystems.com)

*Kits available for Research Use Only*

1. Nguyen, M. H., et al. (In press). Performance of the T2Bacteria Panel for Diagnosing Bloodstream Infections. A Diagnostic Accuracy Study.
2. Mylonakis, E., Clancy, C. J., Ostrosky-Zeichner, et al. (2015). T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. *Clinical Infectious Diseases*, 60(6), 892-899.
3. Clancy, C. J., & Nguyen, M. H. (2013). Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. *Clinical Infectious Diseases*, 56(9), 1284-1292.
4. Cockerill III, F. R., Wilson, J. W., Vetter, E. A., Goodman, K. M., Torgerson, C. A., Harmsen, W. S., ... & Wilson, W. R. (2004). Optimal testing parameters for blood cultures. *Clinical Infectious Diseases*, 38(12), 1724-1730.

T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, T2Dx®, and the T2 Biosystems, Inc. logo are registered trademarks of T2 Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. ©2019 T2 Biosystems. All rights reserved. T2\_717 R04 0319

Distributed by Abacus dx

1800 ABACUS (AUS) 0800 222 170 (NZ) | [info@abacusdx.com](mailto:info@abacusdx.com) | [www.abacusdx.com](http://www.abacusdx.com)

abacus dx